Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 22544 | 7.85 |
09:34 ET | 8801 | 7.87 |
09:36 ET | 880 | 7.84 |
09:38 ET | 500 | 7.81 |
09:39 ET | 6399 | 7.82 |
09:41 ET | 4800 | 7.8 |
09:43 ET | 2300 | 7.8 |
09:45 ET | 1199 | 7.79 |
09:48 ET | 2324 | 7.78 |
09:50 ET | 3949 | 7.74 |
09:52 ET | 8863 | 7.74 |
09:54 ET | 11512 | 7.745 |
09:56 ET | 6427 | 7.75 |
09:57 ET | 8000 | 7.74 |
09:59 ET | 21939 | 7.66 |
10:01 ET | 7216 | 7.685 |
10:03 ET | 6060 | 7.655 |
10:06 ET | 4084 | 7.66 |
10:08 ET | 6840 | 7.67 |
10:10 ET | 4452 | 7.6599 |
10:12 ET | 4556 | 7.67 |
10:14 ET | 16463 | 7.63 |
10:15 ET | 21502 | 7.58 |
10:17 ET | 25322 | 7.56 |
10:19 ET | 17069 | 7.6 |
10:21 ET | 58066 | 7.68 |
10:24 ET | 3600 | 7.72 |
10:26 ET | 5860 | 7.7 |
10:28 ET | 38623 | 7.675 |
10:30 ET | 8581 | 7.69 |
10:32 ET | 5568 | 7.71 |
10:33 ET | 8805 | 7.72 |
10:35 ET | 3528 | 7.75 |
10:37 ET | 2794 | 7.72 |
10:39 ET | 2200 | 7.75 |
10:42 ET | 4619 | 7.76 |
10:44 ET | 510 | 7.74 |
10:46 ET | 496 | 7.73 |
10:48 ET | 4459 | 7.735 |
10:50 ET | 3179 | 7.82 |
10:51 ET | 6098 | 7.79 |
10:53 ET | 498 | 7.77 |
10:55 ET | 2939 | 7.79 |
10:57 ET | 796 | 7.76 |
11:00 ET | 4803 | 7.76 |
11:02 ET | 1900 | 7.75 |
11:04 ET | 2800 | 7.73 |
11:06 ET | 2281 | 7.75 |
11:08 ET | 1411 | 7.73 |
11:09 ET | 3452 | 7.69 |
11:11 ET | 9527 | 7.69 |
11:13 ET | 35837 | 7.76 |
11:15 ET | 1750 | 7.76 |
11:18 ET | 600 | 7.76 |
11:20 ET | 4471 | 7.7678 |
11:22 ET | 3468 | 7.7593 |
11:24 ET | 300 | 7.76 |
11:26 ET | 2801 | 7.75 |
11:27 ET | 3342 | 7.76 |
11:29 ET | 400 | 7.75 |
11:31 ET | 7854 | 7.75 |
11:33 ET | 5764 | 7.74 |
11:36 ET | 6206 | 7.755 |
11:38 ET | 1471 | 7.735 |
11:40 ET | 13427 | 7.835 |
11:42 ET | 13877 | 7.85 |
11:44 ET | 20903 | 7.745 |
11:45 ET | 2437 | 7.72 |
11:47 ET | 2267 | 7.72 |
11:49 ET | 3010 | 7.715 |
11:51 ET | 695 | 7.69 |
11:54 ET | 3800 | 7.695 |
11:56 ET | 1200 | 7.705 |
11:58 ET | 1991 | 7.705 |
12:00 ET | 2410 | 7.73 |
12:02 ET | 5356 | 7.7401 |
12:03 ET | 300 | 7.75 |
12:05 ET | 223 | 7.75 |
12:07 ET | 3753 | 7.78 |
12:09 ET | 1893 | 7.79 |
12:12 ET | 2283 | 7.81 |
12:14 ET | 2210 | 7.81 |
12:16 ET | 2361 | 7.835 |
12:18 ET | 4400 | 7.83 |
12:20 ET | 8307 | 7.83 |
12:21 ET | 3961 | 7.875 |
12:23 ET | 7161 | 7.87 |
12:25 ET | 16366 | 7.93 |
12:27 ET | 2700 | 7.96 |
12:30 ET | 10631 | 7.95 |
12:32 ET | 4617 | 7.92 |
12:34 ET | 13631 | 7.875 |
12:36 ET | 100 | 7.875 |
12:38 ET | 2362 | 7.84 |
12:39 ET | 7200 | 7.84 |
12:41 ET | 7647 | 7.83 |
12:43 ET | 900 | 7.835 |
12:45 ET | 712 | 7.82 |
12:48 ET | 600 | 7.84 |
12:50 ET | 200 | 7.82 |
12:52 ET | 2149 | 7.84 |
12:54 ET | 2700 | 7.84 |
12:56 ET | 2240 | 7.82 |
12:57 ET | 1865 | 7.83 |
12:59 ET | 1200 | 7.835 |
01:01 ET | 2072 | 7.8384 |
01:03 ET | 2722 | 7.85 |
01:06 ET | 6511 | 7.83 |
01:08 ET | 10424 | 7.82 |
01:10 ET | 243 | 7.83 |
01:12 ET | 300 | 7.83 |
01:14 ET | 200 | 7.835 |
01:15 ET | 16115 | 7.83 |
01:17 ET | 3903 | 7.83 |
01:21 ET | 1961 | 7.8101 |
01:24 ET | 5239 | 7.82 |
01:26 ET | 2129 | 7.79 |
01:28 ET | 3304 | 7.79 |
01:30 ET | 791 | 7.79 |
01:32 ET | 1761 | 7.78 |
01:33 ET | 2251 | 7.79 |
01:35 ET | 3928 | 7.81 |
01:37 ET | 1861 | 7.81 |
01:39 ET | 2631 | 7.81 |
01:42 ET | 761 | 7.823 |
01:44 ET | 3775 | 7.83 |
01:46 ET | 4615 | 7.83 |
01:48 ET | 2050 | 7.815 |
01:50 ET | 945 | 7.83 |
01:51 ET | 1049 | 7.83 |
01:53 ET | 1056 | 7.815 |
01:55 ET | 418 | 7.82 |
01:57 ET | 1919 | 7.84 |
02:00 ET | 16812 | 7.92 |
02:02 ET | 15181 | 7.835 |
02:04 ET | 1937 | 7.835 |
02:06 ET | 750 | 7.84 |
02:08 ET | 1500 | 7.849 |
02:09 ET | 1913 | 7.84 |
02:11 ET | 900 | 7.85 |
02:13 ET | 2660 | 7.84 |
02:15 ET | 1110 | 7.81 |
02:18 ET | 7028 | 7.84 |
02:20 ET | 8119 | 7.855 |
02:22 ET | 3738 | 7.85 |
02:24 ET | 3391 | 7.85 |
02:26 ET | 1148 | 7.86 |
02:27 ET | 7748 | 7.88 |
02:29 ET | 4054 | 7.865 |
02:31 ET | 900 | 7.87 |
02:33 ET | 4758 | 7.87 |
02:36 ET | 64629 | 7.9 |
02:38 ET | 4670 | 7.88 |
02:40 ET | 3587 | 7.9 |
02:42 ET | 16443 | 7.92 |
02:44 ET | 1576 | 7.93 |
02:45 ET | 7462 | 7.93 |
02:47 ET | 13529 | 7.9401 |
02:49 ET | 2670 | 7.935 |
02:51 ET | 3837 | 7.89 |
02:54 ET | 4995 | 7.92 |
02:56 ET | 2998 | 7.92 |
02:58 ET | 1497 | 7.93 |
03:00 ET | 900 | 7.915 |
03:02 ET | 3484 | 7.92 |
03:03 ET | 700 | 7.93 |
03:05 ET | 4854 | 7.92 |
03:07 ET | 2447 | 7.91 |
03:09 ET | 5859 | 7.9 |
03:12 ET | 3647 | 7.91 |
03:14 ET | 6664 | 7.92 |
03:16 ET | 2672 | 7.92 |
03:18 ET | 4333 | 7.915 |
03:20 ET | 8499 | 7.94 |
03:21 ET | 2563 | 7.945 |
03:23 ET | 8540 | 7.94 |
03:25 ET | 2596 | 7.9587 |
03:27 ET | 8062 | 7.9705 |
03:30 ET | 8589 | 7.96 |
03:32 ET | 12729 | 7.99 |
03:34 ET | 2348 | 8 |
03:36 ET | 4500 | 8.02 |
03:38 ET | 6107 | 8.01 |
03:39 ET | 35040 | 7.9506 |
03:41 ET | 12474 | 8 |
03:43 ET | 10729 | 7.995 |
03:45 ET | 9631 | 7.965 |
03:48 ET | 6827 | 7.96 |
03:50 ET | 13925 | 7.96 |
03:52 ET | 7031 | 7.95 |
03:54 ET | 12430 | 7.95 |
03:56 ET | 27041 | 7.97 |
03:57 ET | 16766 | 7.955 |
03:59 ET | 65423 | 7.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.6B | -47.9x | --- |
Viking Therapeutics Inc | 5.6B | -54.4x | --- |
Madrigal Pharmaceuticals Inc | 5.9B | -12.0x | --- |
BridgeBio Pharma Inc | 5.2B | -8.6x | --- |
Cytokinetics Inc | 6.0B | -9.6x | --- |
Nuvalent Inc | 5.0B | -32.4x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.